Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Published:2014-09-10 Issue:5 Volume:74 Page:1023-1028
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kodama Tatsushi,Hasegawa Masami,Takanashi Kenji,Sakurai Yuji,Kondoh Osamu,Sakamoto Hiroshi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2578-6.pdf

Reference25 articles.

1. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566

2. Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394

3. Camidge DR, Doebele RC (2012) Treating ALK-positive lung cancer–early successes and future challenges. Nat Rev Clin Oncol 9:268–277

4. Mujoomdar A, Austin JH, Malhotra R et al (2007) Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 242:882–888

5. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48:384–394

Cited by 219 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

2. KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review;OncoTargets and Therapy;2024-08

3. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases;International Journal of Molecular Sciences;2024-06-26

4. Solubility, pH-Solubility Profile, pH-Rate Profile, and Kinetic Stability of the Tyrosine Kinase Inhibitor, Alectinib;Pharmaceuticals;2024-06-13

5. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3